Some PDAC-bearing mice were treated with NK1.1 (PK136) or CD8 (2.43) depleting monoclonal antibodies (mAbs) simultaneously with drug administration to assess whether activation of NK and/or CD8+ T cell immunity was responsible for tumor control. The gene discussed is CD8A; the disease is neoplasm.